On February 8, 2021, Amfora Inc. closed the transaction. The company issued 3,755,878 series B preferred shares at a price of $1.9386 per share for $7,281,145.0908. The transaction included participation from Leaps by Bayer, returning investor Spruce Capital Partners LLC, and new investors BayWa Aktiengesellschaft. The company received funding pursuant to exemption provided under Regulation D from three investors.